Sleep & breathing = Schlaf & Atmung · 2026
Exploratory serum biomarker profiling in idiopathic REM sleep behavior disorder: evidence of early neurodegenerative signatures: a pilot study.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Torres Danielle Mesquita, Pereira Fábio Henrique Queiroz, da Silva Viana Marylane, Ramos Mariana Michilles Santos, Cunha Elisa Gabriela Barros, de Araújo Melo Leonardo José Rodrigues, Sobreira Emmanuelle Silva Tavares, Lopes Francisca Charliane Almino, Frota Annyta Fernandes, Soares Michelle Verde Ramos, de-Almeida Ricardo Titze-, Braga-Neto Pedro, Macedo Danielle S, Sobreira-Neto Manoel Alves
Аннотация
BACKGROUND: Idiopathic REM sleep behavior disorder (iRBD) indicates an early α-synucleinopathy, offering a window for early detection and intervention.
OBJECTIVE: Explore a serum-based biomarker panel, comprising NfL, GFAP, t-tau, and UCH-L1, in patients with iRBD, and compare to individuals with synucleinopathy and healthy controls.
METHOD: This is a cross-sectional, observational study. Serum biomarkers were measured using the single molecule array technique. Clinical evaluation included standardized assessments of sleep, cognitive function, motor symptoms, and psychiatric features.
RESULTS: GFAP levels were significantly higher in the iRBD group than in the control and synucleinopathy groups. Serum NfL levels yielded conflicting results. T-tau and UCHL-1 protein levels were lower in the iRBD and synucleinopathy groups compared to the control group.
CONCLUSION: Our findings suggest that serum levels of NfL, GFAP, t-tau, and UCH-L1 may serve as potential biomarkers in iRBD, primarily GFAP levels.
OBJECTIVE: Explore a serum-based biomarker panel, comprising NfL, GFAP, t-tau, and UCH-L1, in patients with iRBD, and compare to individuals with synucleinopathy and healthy controls.
METHOD: This is a cross-sectional, observational study. Serum biomarkers were measured using the single molecule array technique. Clinical evaluation included standardized assessments of sleep, cognitive function, motor symptoms, and psychiatric features.
RESULTS: GFAP levels were significantly higher in the iRBD group than in the control and synucleinopathy groups. Serum NfL levels yielded conflicting results. T-tau and UCHL-1 protein levels were lower in the iRBD and synucleinopathy groups compared to the control group.
CONCLUSION: Our findings suggest that serum levels of NfL, GFAP, t-tau, and UCH-L1 may serve as potential biomarkers in iRBD, primarily GFAP levels.